UCB bets $2B on Candid's T cell engager ambitions
Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is paying $2 ...
May 3, 2026 09:54 PM EDT DealsChina UCB bets $2 billion on Candid's T cell engager ambitions Kyle LaHucik Biotech Correspondent Ken Song has done it again. The biopharma veteran’s all-out effort to prove T cell engagers’ potential in autoimmune diseases is getting picked up by … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that